Transfusion-dependent thalassemia with ventricular diastolic dysfunction Circulatory System Transfusion-dependent thalassemia with ventricular diastolic dysfunction
Conditions
Interventions
All patients were initially given carvedilol in doses of 0.1 mg/kg/day, the medication being divided into 2 separate doses. The dosage was doubled every two weeks until the target dose of 0.8 mg/kg/da
Sponsors
Thailand Research Fund
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Severe forms of homozygous beta-thalassemia and beta-thalassemia/hemoglobin E disease 2. Transfusion-dependent thalassemia 3. Aged 8-25 years 4. Left ventricular diastolic dysfunction
Exclusion criteria
Exclusion criteria: N/A
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular diastolic function, measured by echocardiography at the baseline and 3 and 6 months after treatment. Echocardiographic data included pulse wave Doppler assessment of mitral and pulmonary venous flows (ventricular diastolic filling analysis) and tissue Doppler imaging. Diastolic left ventricular dysfunction was graded according to pulse wave Doppler of mitral and pulmonary venous flows and tissue Doppler imaging. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects of carvedilol use, assessed at the baseline and 3 and 6 months after treatment: 1. Blood pressure 2. Heart rate 3. Symptoms such as dizziness, chest pain and swelling | — |
Countries
Thailand
Outcome results
None listed